IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2238
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$274M
Ian B. McDonald
Bright Minds Biosciences Inc. develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$DRUG BRIGHT MINDS BIOSCIENCES INC. | 49 | 27 | 36 | 85 | - | - | -59.6% | -57.9% | - | - | - | -30.9% | 0.0% | 0.0x | $274M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
BRIGHT MINDS BIOSCIENCES INC. (DRUG) receives a "Reduce" rating with a composite score of 48.6/100. It ranks #2238 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for DRUG.
View All RatingsROE proxy -59.6% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth -31%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate BRIGHT MINDS BIOSCIENCES INC. (DRUG) as a Reduce with a composite score of 48.6/100 at a current price of $89.21. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
BRIGHT MINDS BIOSCIENCES INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 48.6/100 places it at rank #2238 in our full universe.
The near-term outlook is constructive, with revenue growing at -31% and momentum in the 85th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
High
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
BRIGHT MINDS BIOSCIENCES INC. represents a reduce based on multi-factor quantitative performance.
BRIGHT MINDS BIOSCIENCES INC. receives a Reduce rating from our analysis, with a composite score of 48.6/100 and 2 out of 5 stars, ranking #2238 out of 7,333 stocks. DRUG's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
DRUG's quality score of 27/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -59.6% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 36/100, DRUG appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 14.12x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
BRIGHT MINDS BIOSCIENCES INC.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -30.9% vs. a sector average of 6.7% and a return on assets of -57.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
DRUG shows strong momentum characteristics with a score of 85/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at -30.9% year-over-year, while a beta of 3.84 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 48/100, DRUG exhibits average financial resilience. Key stability metrics include a beta of 3.84 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 53/100 for DRUG suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 3.84), micro-cap liquidity risk. With a $274M market cap (micro-cap), BRIGHT MINDS BIOSCIENCES INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
BRIGHT MINDS BIOSCIENCES INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2238 of 7,333 overall (69th percentile). Key comparisons include ROE of -59.6% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While DRUG currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (25) would have the largest impact on the composite score.
ROE 3038% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the most promising stocks. TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares. The update […]

Bright Minds Biosciences (NASDAQ: DRUG) successfully closed a public offering of 1.945 million common shares at US$90 per share, raising US$175.05 million in gross proceeds. The company plans to use the net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, Prader-Willi Syndrome, and BMB-105, along with R&D and general corporate purposes.

Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss. Decibel Therapeutics, Inc. (NASDAQ: DBTX) gained 76% to $4.9150 after Regeneron announced it will acquire the company. Benitec Biopharma Inc. (NASDAQ: BNTC) jumped 75.8% to $3.3937. Benitec Biopharma reported pricing of $30 million underwritten public offering. Renovaro Biosciences Inc. (NASDAQ: RENB) shares gained 68.2% to $1.43 after the company and AI-focused GEDi Cube announced a binding, exclusive letter of intent to merge. T Stamp Inc. (NASDAQ: IDAI) climbed 48.8% to $2.3518. EBET, Inc. (NASDAQ: EBET) surged 40.5% to $0.0405 on abnormally-high volume. The stock was set to be suspended at the opening of business today unless the company requested an appeal of Nasdaq's Listing Qualifications Department's determination. Millennium Group International Holdings Limited (NASDAQ: MGIH) gained 40% to $2.7003 on strong volume. Science 37 Holdings, Inc. (NASDAQ: SNCE) jumped 39.3% to $0.3765 following better-than-expected quarterly results. BioNexus Gene Lab Corp. (NASDAQ: BGLC) gained 36.5% to $1.5699. Kubient, Inc. (NASDAQ: KBNT) rose 33.7% to $0.63. Oportun Financial Corporation (NASDAQ: OPRT) gained 31.3% to $6.90 following strong quarterly results. Poseida Therapeutics, Inc. (NASDAQ: PSTX) climbed 31.3% to $2.60 following quarterly results. Mirati Therapeutics, Inc. (NASDAQ: MRTX) surged 30.1% to $36.17 after the company reported second-quarter financial results. Also, B. Riley Securities upgraded the stock from Neutral to Buy and announced a $45 price target. Allbirds, Inc. (NASDAQ: BIRD) gained 29% to $1.65 after the company reported better-than-expected second-quarter financial results. Array Technologies, Inc. (NASDAQ: ARRY) climbed 27.8% to $22.85 following a second-quarter earnings beat. Computer Task Group, Incorporated (NASDAQ: CTG) gained 27.8% to $10.23 after the company announced it will be acquired by Cegeka for $10.50 per share. LivePerson, Inc. (NASDAQ: LPSN) rose 27.5% to $5.09 r after the company announced a second-quarter earnings beat. The company named John Collins as the Interim CEO. PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) gained 22.3% to $8.31 after the company reported better-than-expected second-quarter EPS results. Celsius Holdings, Inc. (NASDAQ: CELH) jumped 21.8% to $174.73 after the company reported better-than-expected second-quarter financial results. United Insurance Holdings Corp. (NASDAQ: UIHC) gained 21.3% to $6.83. DMC Global Inc. (NASDAQ: BOOM) climbed 19.8% to $21.03 following quarterly results. Dutch Bros Inc. (NYSE: BROS) surged 19.8% to $33.55 after the company reported better-than-expected quarterly EPS results and issued FY23 guidance. Azenta, Inc. (NASDAQ: AZTA) gained 19.6% to $57.45 fter the company reported better-than-expected third-quarter financial results and issued fourth-quarter EPS guidance above estimates. Additionally, Needham raised its price target from $55 to $65 on the stock. ThredUp Inc. (NASDAQ: TDUP) climbed 19.5% to $3.85 after the company reported better-than-expected second-quarter financial results and issued revenue guidance. Also, Goldman Sachs raised its price target from $3 to $4 on the stock. Planet Green Holdings Corp. (NASDAQ: PLAG) rose 17.5% to $0.5670. Anavex Life Sciences Corp. (NASDAQ: AVXL) climbed 16.2% to $ 9.33. Rapid7, ...

Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser technology. Vivos Therapeutics, Inc. (NASDAQ: VVOS) gained 91.1% to $0.4987 after falling more than 10% on Monday. Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 87.6% to $6.04 after the company disclosed data for BMB-101. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) shares jumped 63.9% to $0.1472 after falling over 25% on Monday. The company recently announced its plans to reduce the company's headcount by 78%. Gorilla Technology Group Inc. (NASDAQ: GRRR) rose 32.2% to $2.04 as the company hired Global Economics Group for due diligence, advancing in battle against illegal short selling. Paymentus Holdings, Inc. (NYSE: PAY) shares gained 29.4% to $13.76 after reporting better-than-expected quarterly results. Bionomics Limited (NASDAQ: BNOX) jumped 24% to $1.60. Kyndryl Holdings, Inc. (NYSE: KD) gained 23% to $15.32 after the company raised its FY24 earnings outlook and said it expects its fiscal 2024 adjusted free cash flow will be positive. ePlus inc. (NASDAQ: PLUS) rose 20.8% to $69.99 following better-than-expected quarterly results. Quanterix Corporation (NASDAQ: QTRX) gained 20.4% to $26.17 after reporting upbeat quarterly results. Sterling Infrastructure, Inc. (NASDAQ: STRL) surged 19.9% to $74.12 after reporting upbeat quarterly results. CECO Environmental Corp. (NASDAQ: CECO) rose 19.3% to $14.01 after the company posted upbeat quarterly sales and increased FY23 revenue guidance. Tilray Brands, Inc. (NASDAQ: TLRY) climbed 19% to $2.6484 after the Canadian cannabis and packaged goods company announced a deal to acquire eight beer brands from Anheuser-Busch Inbev. Viant Technology Inc. (NASDAQ: DSP) gained 18.2% to $5.42 following strong quarterly results. Latham Group, Inc. (NASDAQ: SWIM) gained 18.1% to $4.50 following strong quarterly sales. WW International, Inc. (NASDAQ: WW) jumped 18.1% to $9.45. MannKind Corporation (NASDAQ: MNKD) rose 17.7% to $5.41 following strong quarterly results. Novo Nordisk A/S (NYSE: NVO) climbed 17.4% to $189.48 after the company announced headline results from the SELECT cardiovascular outcomes trial showing Semaglutide 2.4 mg reduced risk of major adverse cardiovascular events by 20%. Eli Lilly and Company (NYSE: LLY) rose 16.6% to $529.61 after the company raised its FY23 guidance. The company also reported better-than-expected second-quarter earnings, including strong Mounjaro sales growth. DocGo Inc. (NASDAQ: DCGO) gained 16.3% to $10.59 following upbeat sales. United States Cellular Corporation (NYSE: USM) jumped 15.2% to $36.00. JP Morgan upgraded United States Cellular from Neutral to Overweight. AdaptHealth Corp. (NASDAQ:

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling over 200 points on Tuesday. The Dow traded down 0.64% to 35,246.87 while the NASDAQ fell 0.98% to 13,857.43. The S&P 500, also fell, dropping, 0.65% to 4,489.12. Check This Out: Top 5 Tech Stocks Which Could Rescue Your Portfolio This Month Leading and Lagging Sectors Health care shares jumped by 0.3% on Tuesday. In trading on Tuesday, financial shares fell 1.3%. Top Headline United Parcel Service Inc (NYSE: UPS) reported mixed second-quarter financial results and issued FY23 revenue guidance below estimates. United Parcel Service reported a second-quarter FY23 revenue decline of 10.9% year-over-year to $22.055 billion, missing the consensus of $23.11 billion. Adjusted EPS was $2.54, compared to $3.29, beating the consensus of $2.50. For FY23, UPS now expects consolidated revenue to be about $93 billion (prior $97 billion) Vs. consensus of $96.77 billion and an adjusted operating margin of around 11.8% (prior 12.8%). Equities Trading UP Nuburu, Inc. (NYSE: BURU) shares shot up 38% to $14.31 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser technology. Shares of Paymentus Holdings, Inc. (NYSE: PAY) got a boost, shooting 34% to $14.31 after the company reported better-than-expected second-quarter financial results. Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares were also up, gaining 36% to $4.37 after the company disclosed data for BMB-101. Equities Trading ...